| Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (NCT04939272) | City of Hope Medical Center | 2022-06-29 |
| Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (NCT05249959) | Fondazione Italiana Linfomi - ETS | 2022-03-21 |
| Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma (NCT04990778) | M.D. Anderson Cancer Center | 2021-11-30 |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (NCT05025800) | M.D. Anderson Cancer Center | 2021-10-13 |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (NCT04995536) | City of Hope Medical Center | 2021-07-27 |
| Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy (NCT04703686) | The Lymphoma Academic Research Organisation | 2021-03-30 |
| Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial (NCT04872413) | M.D. Anderson Cancer Center | 2021-03-04 |
| Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (NCT04484012) | City of Hope Medical Center | 2020-12-31 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (NCT04578600) | Joseph Tuscano | 2020-10-23 |
| CD19-Specific T Cells Post AlloSCT (NCT03579888) | M.D. Anderson Cancer Center | 2020-06-26 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies (NCT04205409) | University of Washington | 2020-06-05 |
| Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (NCT04047797) | M.D. Anderson Cancer Center | 2019-08-28 |
| Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (NCT03946878) | M.D. Anderson Cancer Center | 2019-08-13 |
| Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (NCT04054167) | M.D. Anderson Cancer Center | 2019-06-14 |
| Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma (NCT03219047) | M.D. Anderson Cancer Center | 2018-12-20 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCT03479268) | City of Hope Medical Center | 2018-04-27 |
| Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (NCT03440567) | City of Hope Medical Center | 2018-04-02 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729) | Fred Hutchinson Cancer Center | 2017-12-05 |
| Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma (NCT03147885) | Barbara Ann Karmanos Cancer Institute | 2017-06-20 |
| Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma (NCT03061188) | Northwestern University | 2017-05-23 |
| Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (NCT03206970) | BeiGene | 2017-03-02 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT02950220) | Kami Maddocks | 2017-01-12 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (NCT02568553) | National Cancer Institute (NCI) | 2016-11-15 |
| Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant (NCT02869633) | Vanderbilt-Ingram Cancer Center | 2016-11-01 |
| Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma (NCT02736617) | OHSU Knight Cancer Institute | 2016-07-05 |
| Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT02420795) | M.D. Anderson Cancer Center | 2015-11-03 |
| Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (NCT02051257) | City of Hope Medical Center | 2014-06-19 |
| Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies (NCT01921387) | Fred Hutchinson Cancer Center | 2013-10-09 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT01955499) | National Cancer Institute (NCI) | 2013-09-24 |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (NCT01897012) | National Cancer Institute (NCI) | 2013-07-17 |
| Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT01880567) | M.D. Anderson Cancer Center | 2013-07-15 |
| Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia (NCT01865617) | Fred Hutchinson Cancer Center | 2013-05-22 |
| Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT01719250) | Mayo Clinic | 2012-12-01 |
| Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (NCT01695941) | National Cancer Institute (NCI) | 2012-08-31 |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma (NCT01381692) | National Cancer Institute (NCI) | 2011-07-20 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (NCT00723099) | Fred Hutchinson Cancer Center | 2008-06-25 |